Tiludronate (BioDeep_00000006671)
Secondary id: BioDeep_00001868556
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
{[(4-chlorophenyl)sulfanyl](phosphono)methyl}phosphonic acid
化学式: C7H9ClO6P2S (317.9284)
中文名称: 替鲁膦酸
谱图信息:
最多检出来源 Homo sapiens(blood) 40.91%
分子结构信息
SMILES: C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl
InChI: InChI=1S/C7H9ClO6P2S/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14/h1-4,7H,(H2,9,10,11)(H2,12,13,14)
描述信息
Tiludronate is only found in individuals that have used or taken this drug. It is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates.The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. In vitro studies indicate that tiludronate acts primarily on bone through a mechanism that involves inhibition of osteoclastic activity with a probable reduction in the enzymatic and transport processes that lead to resorption of the mineralized matrix. Bone resorption occurs following recruitment, activation, and polarization of osteoclasts. Tiludronate appears to inhibit osteoclasts by at least two mechanisms: disruption of the cytoskeletal ring structure, possibly by inhibition of protein-tyrosine-phosphatase, thus leading to detachment of osteoclasts from the bone surface and the inhibition of the osteoclastic proton pump.
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
同义名列表
11 个代谢物同义名
{[(4-chlorophenyl)sulfanyl](phosphono)methyl}phosphonic acid; (4-Chlorophenyl)thiomethylene bisphosphonic acid; (Chloro-4-phenyl)thiomethylene bisphosphonate; (Chloro-4-phenyl)thiomethylene biphosphonate; Tiludronic acid disodium salt; Tiludronate disodium; Tiludronic Acid; Tiludronate; CL2SMBP; Skelid; Tiludronic acid
数据库引用编号
16 个数据库交叉引用编号
- ChEBI: CHEBI:9598
- KEGG: C08141
- KEGGdrug: D08599
- PubChem: 60937
- HMDB: HMDB0015265
- Metlin: METLIN66833
- DrugBank: DB01133
- ChEMBL: CHEMBL1350
- Wikipedia: Tiludronic acid
- chemspider: 54905
- CAS: 89987-06-4
- PMhub: MS000019749
- PubChem: 10341
- NIKKAJI: J476.064F
- RefMet: Tiludronate
- KNApSAcK: 9598
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Chris M Riggs, Sarah L Thompson, Yat-Ming So, Jenny K Y Wong, Terence S M Wan, Paul Robinson, Brian D Stewart, Emmie N M Ho. Tiludronic acid can be detected in blood and urine samples from Thoroughbred racehorses over 3 years after last administration.
Equine veterinary journal.
2021 Nov; 53(6):1287-1295. doi:
10.1111/evj.13395. [PMID: 33247964] - Andrea Bertuglia, Ilaria Basano, Eleonora Pagliara, Nika Brkljaca Bottegaro, Giuseppe Spinella, Michela Bullone. Effect of intravenous tiludronate disodium administration on the radiographic progression of osteoarthritis of the fetlock joint in Standardbred racehorses.
Journal of the American Veterinary Medical Association.
2021 09; 259(6):651-661. doi:
10.2460/javma.259.6.651. [PMID: 34448617] - Katja F Düsterdieck-Zellmer. [Use of bisphosphonates in horses - a review].
Tierarztliche Praxis. Ausgabe G, Grosstiere/Nutztiere.
2018 Oct; 46(5):323-333. doi:
10.15653/tpg-170804. [PMID: 30340242] - M A Popot, M Jacobs, P Garcia, B Loup, J Guyonnet, P L Toutain, L Bailly-Chouriberry, Y Bonnaire. Pharmacokinetics of tiludronate in horses: A field population study.
Equine veterinary journal.
2018 Jul; 50(4):488-492. doi:
10.1111/evj.12789. [PMID: 29194746] - Jo Gourlay. Licence variations regarding tiludronate disodium.
The Veterinary record.
2015 Oct; 177(16):423-4. doi:
10.1136/vr.h5621. [PMID: 26494897] - M A Popot, P Garcia, C Hubert, A Bolopion, L Bailly-Chouriberry, Y Bonnaire, D Thibaud, J Guyonnet. HPLC/ESI-MS(n) method for non-amino bisphosphonates: application to the detection of tiludronate in equine plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2014 May; 958(?):108-16. doi:
10.1016/j.jchromb.2014.03.018. [PMID: 24732148] - Laëtitia Michou, Jacques P Brown. Emerging strategies and therapies for treatment of Paget's disease of bone.
Drug design, development and therapy.
2011; 5(?):225-39. doi:
10.2147/dddt.s11306. [PMID: 21607019] - Michael Pazianas, Cyrus Cooper, F Hal Ebetino, R Graham G Russell. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
Therapeutics and clinical risk management.
2010 Jul; 6(?):325-43. doi:
10.2147/tcrm.s8054. [PMID: 20668715] - J P Walsh, R Attewell, B G A Stuckey, M J Hooper, J D Wark, S Fletcher, V Ferrari, J A Eisman. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
Bone.
2008 Jun; 42(6):1219-25. doi:
10.1016/j.bone.2008.01.024. [PMID: 18353737] - C Delguste, H Amory, J Guyonnet, D Thibaud, P Garnero, J Detilleux, O M Lepage, M Doucet. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.
Journal of veterinary pharmacology and therapeutics.
2008 Apr; 31(2):108-16. doi:
10.1111/j.1365-2885.2007.00936.x. [PMID: 18307502] - P Peris, L Alvarez, S Vidal, M A Martínez, A Monegal, N Guañabens. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Clinical and experimental rheumatology.
2007 Mar; 25(2):206-10. doi:
. [PMID: 17543143] - P Peris, L Alvarez, S Vidal, D Kasper, D J Leeming, A Monegal, M Angeles Martínez, F Pons, N Guañabens. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
Calcified tissue international.
2006 Jul; 79(1):22-6. doi:
10.1007/s00223-005-0247-9. [PMID: 16868670] - Philippe Orcel, Mickaël Rousière. [Paget's disease and its therapeutic management].
Presse medicale (Paris, France : 1983).
2005 Apr; 34(8):612-6. doi:
10.1016/s0755-4982(05)83991-0. [PMID: 15962504] - Peter Alexandersen, Pilar Peris, Nuria Guañabens, Inger Byrjalsen, Luisa Alvarez, Helene Solberg, Paul Ac Cloos. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2005 Apr; 20(4):588-95. doi:
10.1359/jbmr.041212. [PMID: 15765177] - F Journe, C Chaboteaux, J-C Dumon, G Leclercq, G Laurent, J-J Body. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
British journal of cancer.
2004 Nov; 91(9):1703-10. doi:
10.1038/sj.bjc.6602181. [PMID: 15477866] - L Alvarez, P Peris, N Guañabens, S Vidal, Ll Quintó, A Monegal, F Pons, A M Ballesta, J Muñoz-Gómez. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Rheumatology (Oxford, England).
2004 Jul; 43(7):869-74. doi:
10.1093/rheumatology/keh185. [PMID: 15054158] - J Donáth, M Krasznai, B Fornet, P Gergely, G Poór. Effect of bisphosphonate treatment in patients with Paget's disease of the skull.
Rheumatology (Oxford, England).
2004 Jan; 43(1):89-94. doi:
10.1093/rheumatology/keg477. [PMID: 12923287] - O Fromigue, N Kheddoumi, J-J Body. Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.
British journal of cancer.
2003 Jul; 89(1):178-84. doi:
10.1038/sj.bjc.6601009. [PMID: 12838321] - L Alvarez, P Peris, N Guañabens, S Vidal, I Ros, F Pons, X Filella, A Monegal, J Muñoz-Gomez, A M Ballesta. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Arthritis and rheumatism.
2003 Mar; 48(3):824-8. doi:
10.1002/art.10834. [PMID: 12632438] - Martin Pecherstorfer, Karin Brenner, Niklas Zojer. Current management strategies for hypercalcemia.
Treatments in endocrinology.
2003; 2(4):273-92. doi:
10.2165/00024677-200302040-00005. [PMID: 15966562] - Pilar Peris, Luisa Alvarez, Ana Monegal, Núria Guañabens, Magdalena Durán, Mónica Echevarría, Inmaculada Ros, Antonio M Ballesta, José Muñoz-Gómez. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
Journal of bone and mineral metabolism.
2002; 20(2):116-20. doi:
10.1007/s007740200016. [PMID: 11862534] - L Alvarez, N Guañabens, P Peris, S Vidal, I Ros, A Monegal, J L Bedini, R Deulofeu, F Pons, J Muñoz-Gomez, A M Ballesta. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Bone.
2001 Nov; 29(5):447-52. doi:
10.1016/s8756-3282(01)00592-0. [PMID: 11704497] - W M Drake, D L Kendler, J P Brown. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Clinical therapeutics.
2001 Apr; 23(4):620-6. doi:
10.1016/s0149-2918(01)80065-5. [PMID: 11354395] - J Y Reginster, C Christiansen, C Roux, J Fechtenbaum, A Rouillon, K P Tou. Intermittent cyclic tiludronate in the treatment of osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2001; 12(3):169-77. doi:
10.1007/s001980170126. [PMID: 11315234] - S Bohic, C Rey, A Legrand, H Sfihi, R Rohanizadeh, C Martel, A Barbier, G Daculsi. Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment.
Bone.
2000 Apr; 26(4):341-8. doi:
10.1016/s8756-3282(99)00276-8. [PMID: 10719276] - A Morales-Piga. Tiludronate. A new treatment for an old ailment: Paget's disease of bone.
Expert opinion on pharmacotherapy.
1999 Nov; 1(1):157-70. doi:
10.1517/14656566.1.1.157. [PMID: 11249559] - H Davi, C Tronquet, J Caix, J Simiand, C Briot, Y Berger, J F Thiercelin. Disposition of tiludronate (Skelid) in animals.
Xenobiotica; the fate of foreign compounds in biological systems.
1999 Oct; 29(10):1017-31. doi:
10.1080/004982599238083. [PMID: 10574683] - G A Maier, G F Lockwood, J A Oppermann, G Wei, P Bauer, J Fedler-Kelly, T Grasela. Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies.
European journal of drug metabolism and pharmacokinetics.
1999 Jul; 24(3):249-54. doi:
10.1007/bf03190028. [PMID: 10716064] - S Luurila, S Kautiainen, P Ylitalo, R Ylitalo. Pharmacokinetics of bisphosphonates in rabbits.
Pharmacology & toxicology.
1999 Jan; 84(1):24-8. doi:
10.1111/j.1600-0773.1999.tb02106.x. [PMID: 9974186] - S Kautiainen, S Luurila, P Ylitalo, R Ylitalo. Transformation of bisphosphonates into insoluble material in human blood in vitro.
Methods and findings in experimental and clinical pharmacology.
1998 May; 20(4):289-95. doi:
10.1358/mf.1998.20.4.485682. [PMID: 9658377] - A Morales Piga, V Abraira Santos, J S Rey Rey, F de Abajo Iglesias. [Factors that determine intensity of response to treatment with tiludronate in Paget's disease].
Medicina clinica.
1998 Feb; 110(7):254-8. doi:
NULL. [PMID: 9562949] - H Ohnishi, T Nakamura, K Narusawa, H Murakami, M Abe, A Barbier, K Suzuki. Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats.
Bone.
1997 Oct; 21(4):335-43. doi:
10.1016/s8756-3282(97)00145-2. [PMID: 9315337] - A Morales-Piga, J Del Pino, A Rapado, M Diaz-Curiel, M Pallares, J Gonzalez-Macias. Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone.
Clinical therapeutics.
1997 Sep; 19(5):963-74. doi:
10.1016/s0149-2918(97)80049-5. [PMID: 9385484] - W D Fraser, T C Stamp, R A Creek, J P Sawyer, C Picot. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.
Postgraduate medical journal.
1997 Aug; 73(862):496-502. doi:
10.1136/pgmj.73.862.496. [PMID: 9307742] - H Murakami, N Takahashi, S Tanaka, I Nakamura, N Udagawa, S Nakajo, K Nakaya, M Abe, Y Yuda, F Konno, A Barbier, T Suda. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.
Bone.
1997 May; 20(5):399-404. doi:
10.1016/s8756-3282(97)00025-2. [PMID: 9145236] - P Ravn, M Rix, H Andreassen, B Clemmesen, M Bidstrup, M Gunnes. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women.
Calcified tissue international.
1997 Mar; 60(3):255-60. doi:
10.1007/s002239900225. [PMID: 9069162] - H A Fleisch. Bisphosphonates: preclinical aspects and use in osteoporosis.
Annals of medicine.
1997 Feb; 29(1):55-62. doi:
10.3109/07853899708998743. [PMID: 9073324] - P David, H Nguyen, A Barbier, R Baron. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
1996 Oct; 11(10):1498-507. doi:
10.1002/jbmr.5650111017. [PMID: 8889850] - C de la Piedra, A Rapado, E M Díaz Diego, M A Díaz Martín, C Aguirre, E López Gavilanes, M Díaz Curiel. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
Calcified tissue international.
1996 Aug; 59(2):95-9. doi:
10.1007/s002239900093. [PMID: 8687976] - H R Schwietert, P A Peeters, J Dingemanse, J F Thiercelin, J Necciari, H de Bruin, J H Jonkman. Multiple dose pharmacokinetics of tiludronate in healthy volunteers.
European journal of clinical pharmacology.
1996; 51(2):175-81. doi:
10.1007/s002280050181. [PMID: 8911885] - C Roux. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
Bone.
1995 Nov; 17(5 Suppl):497S-499S. doi:
10.1016/8756-3282(95)00278-x. [PMID: 8573426] - C H Chesnut. Tiludronate: development as an osteoporosis therapy.
Bone.
1995 Nov; 17(5 Suppl):517S-519S. doi:
10.1016/8756-3282(95)00277-8. [PMID: 8573430] - M R McClung, C K Tou, N H Goldstein, C Picot. Tiludronate therapy for Paget's disease of bone.
Bone.
1995 Nov; 17(5 Suppl):493S-496S. doi:
10.1016/8756-3282(95)00282-1. [PMID: 8573425] - L N Sansom, J Necciari, J F Thiercelin. Human pharmacokinetics of tiludronate.
Bone.
1995 Nov; 17(5 Suppl):479S-483S. doi:
10.1016/8756-3282(95)00259-6. [PMID: 8573422] - C Roux, C Gennari, J Farrerons, J P Devogelaer, H Mulder, H P Kruse, C Picot, L Titeux, J Y Reginster, M Dougados. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.
Arthritis and rheumatism.
1995 Jun; 38(6):851-8. doi:
10.1002/art.1780380620. [PMID: 7779130] - P D Delmas, P Vergnaud, M E Arlot, P Pastoureau, P J Meunier, M H Nilssen. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?.
Bone.
1995 Jun; 16(6):603-10. doi:
10.1016/8756-3282(95)00113-r. [PMID: 7669436] - J Y Reginster, R Treves, J C Renier, B Amor, J Sany, D Ethgen, C Picot, P Franchimont. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
1994 May; 9(5):615-9. doi:
10.1002/jbmr.5650090505. [PMID: 8053389] - J Y Reginster, M P Lecart, R Deroisy, D Ethgen, B Zegels, P Franchimont. Paget's disease of bone treated with a five day course of oral tiludronate.
Annals of the rheumatic diseases.
1993 Jan; 52(1):54-7. doi:
10.1136/ard.52.1.54. [PMID: 8427515] - J Y Reginster, F Colson, G Morlock, B Combe, D Ethgen, P Geusens. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
Arthritis and rheumatism.
1992 Aug; 35(8):967-74. doi:
10.1002/art.1780350819. [PMID: 1642662] - J C Dumon, A Magritte, J J Body. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.
Bone and mineral.
1991 Dec; 15(3):257-66. doi:
10.1016/0169-6009(91)90131-i. [PMID: 1773138] - P Gaudin, R Juvin, K Sirajedine, M Foret, D Cordonnier, X Phelip. [Arthropathy of the fingers in hemodialyzed patients with chronic renal failure. Apropos of a study of 44 patients].
Revue du rhumatisme et des maladies osteo-articulaires.
1991 Jan; 58(1):7-11. doi:
NULL. [PMID: 1871524] - J Y Reginster, M P Lecart, R Deroisy, N Sarlet, D Denis, D Ethgen, J Collette, P Franchimont. Prevention of postmenopausal bone loss by tiludronate.
Lancet (London, England).
1989 Dec; 2(8678-8679):1469-71. doi:
10.1016/s0140-6736(89)92927-9. [PMID: 2574764] - J Y Reginster, R Deroisy, M P Lecart, P Franchimont. (Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease.
Acta Belgica. Medica physica : organe officiel de la Societe royale belge de medecine physique et de rehabilitation.
1989 Apr; 12(2):47-52. doi:
NULL. [PMID: 2603591] - M Audran, P Clochon, D Etghen, B Mazieres, J C Renier. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate.
Clinical rheumatology.
1989 Mar; 8(1):71-9. doi:
10.1007/bf02031073. [PMID: 2663323] - J Y Reginster, A M Jeugmans-Huynen, A Albert, D Denis, R Deroisy, M P Lecart, M A Fontaine, J Collette, P Franchimont. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone.
Bone.
1988; 9(6):349-54. doi:
10.1016/8756-3282(88)90115-9. [PMID: 3073800]
